5 Most Undervalued Value Stocks To Buy Now

4. Moderna, Inc. (NASDAQ:MRNA)

PE Ratio as of October 21 (TTM): 3.95 

Number of Hedge Fund Holders: 45

Moderna, Inc (NASDAQ:MRNA) is a clinical-stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. The company is well–run, with a market capitalization of over $50 billion, as of October 21, and is ranked high among the best undervalued stocks to buy now. As of October 21, Moderna, Inc. (NASDAQ:MRNA) is trading at a PE multiple of 4x. On October 12, Piper Sandler analyst Edward Tenthoff reiterated his Overweight rating and $214 price target on Moderna, Inc. (NASDAQ:MRNA).

At the close of Q2 2022, 45 hedge funds were long Moderna, Inc. (NASDAQ:MRNA) and held stakes worth $2.63 billion in the company. As of  September 30, ARK Investment Management is the largest shareholder in Moderna, Inc. (NASDAQ:MRNA) and has stakes worth $19.34 million in the company.

Here is what Baron Funds had to say about Moderna, Inc. (NASDAQ:MRNA) in its third-quarter 2022 investor letter:

“Within biotechnology, underperformance of Moderna, Inc. (NASDAQ:MRNA) and lower exposure to this better performing sub-industry weighed the most on relative performance. Shares of Moderna, a leader in the emerging field of mRNA-based vaccines and therapeutics, declined due to increasing uncertainty around what a booster market could look like as COVID shifts away from pandemic status and becomes an increasingly commercial market rather than government funded.”